A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Phase 3 Active not recruiting 80 enrolled Alexion Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

Timeline

Start: 2022-10-28
Primary completion: 2026-08-24
Completion: 2026-08-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Danicopan	Small molecule	—	Oral

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Summary

Timeline

Drugs

Indications